CAC
AQST icon

Cowen and Company’s Aquestive Therapeutics AQST Stock Holding History

Cowen and Company’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-124,590
Closed -$80K – 669
2022
Q2 		$80K Buy
+124,590
New +$166K 0.01% 262

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LI
Latash Investments Anchorage, Alaska $129M AUM 14.69% 1-Year Est. Return

Cowen and Company's AQST Position: Q3 2022 in Review

Cowen and Company sold out of Aquestive Therapeutics (AQST) in Q3 2022, closing a stake of 124,590 shares — an estimated $80K sold.

Cowen and Company first reported a position in AQST in Q2 2022 and held it in 1 quarter. The position peaked at $80K in Q2 2022. 46 funds tracked by Wall St. Rank hold AQST as of Q3 2022.

  • Cowen and Company reported no remaining Aquestive Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Cowen and Company sold 124,590 Aquestive Therapeutics shares in Q3 2022, an estimated $80K.
  • Cowen and Company first reported a position in Aquestive Therapeutics in Q2 2022 and held it in 1 quarter.
  • Cowen and Company's Aquestive Therapeutics position peaked at $80K in Q2 2022.
  • 46 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2022.

Based on Cowen and Company's 13F filing for Q3 2022, filed 14 Nov 2022.